Dermatology

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

New research was conducted into treating Stevens-Johnson syndrome/toxic epidermal necrolysis patients with plasmapheresis before intravenous immunoglobulin therapy.

A new study indicated that body surface area predicted erythema-type chronic graft-vs-host disease survival more accurately than NIH Skin Scores.

Drs Raj Chovatiya, George Han, and Vivian Shi review the current challenges and opportunities surrounding the utilization and availability of biologic therapies in atopic dermatitis.

Expert dermatologists highlight the burden of atopic dermatitis in young children and examine the clinical data for dupilumab, a biologic treatment for this age group.

The expert panel discusses the heterogeneity of atopic dermatitis manifestation and therapy decisions for individual patients.

Dr Vivian Shi provides an overview of treatment options for atopic dermatitis patients in different age groups.

New data demonstrated that the combined use of prednisone and methotrexate saw positive results in hair regrowth for patients with alopecia totalis or alopecia universalis.

In a research letter, patient perspectives were explored regarding access to dermatology clinic notes, with more than half reporting improved understanding due to notes.

Novan announced on Tuesday that the FDA accepted the New Drug Application (NDA) for Berdazimer Gel, a topical antiviral molluscum contagiosum treatment, for review.

At the AAAAI 2023 Annual Meeting, Dr. Debajyoti Ghosh explains the importance of understanding the effect of phthalates, specifically di-2-ethylhexyl phthalate (DEHP).

New findings have indicated that alopecia areata, alopecia totalis, and alopecia universalis, may disproportionately affect Asian Americans and other people of color.

Data shown at the AAAAI annual meeting showed that chronic spontaneous urticaria activity and DLQI rankings were higher following dupilumab treatment.

Verrica Pharmaceutical's drug-device combination will be decided upon as potentially the first molluscum drug in July.

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In an interview segment with Kirby, she described her views on the need for future research into povorcitinib for hidradenitis suppurativa patients, as well as her outlook on treatment.

In the interview, Kirby discussed recent trial data on povorcitinib indicating significant decreases in total abscess and inflammatory nodule count for hidradenitis suppurativa patients.

In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

In an interview with Maria Teresa García-Romero, MD, MPH, a discussion was held regarding the need for a morphea severity tool for pediatric patients.

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

Mental health outcomes for those with hidradenitis suppurativa who have had a previous surgery were explored in recent research.

New research explored associations between lesions resulting from Degos and diffuse cutaneous systemic sclerosis.

An interview segment with Alexa Kimball, MD, MPH, in which she describes further updates on 52 week trial data in the SUNRISE and SUNSHINE trials for HS.